Galectin Therapeutics Inc. (GALT)
Last updated: 2026-10-21 12:48:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Galectin Therapeutics Inc. (GALT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.51, with a market capitalization of $352.47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.03 to $7.13. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$352.47M | |
$3.49 | |
$19.11 | |
$0.49 | |
$3.43 | |
25.00 | |
307.75K | |
-- | |
$7.13 | |
$2.03 | |
-- | |
-- |
Galectin Therapeutics Inc. (GALT) Pre-Market Stock Price
Galectin Therapeutics Inc. (GALT) is trading at $3.51 in pre-market trading as of 2026-10-21 11:59:00, up 2.45% ($0.08) from the previous close of $3.43
Pre-market trading shows how investors are pricing GALT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Galectin Therapeutics Inc. (GALT) 7-Day Stock Price Change
Over the past seven days, Galectin Therapeutics Inc. (GALT) moved from $3.87 to $3.51, representing a decline of 9.20% ($0.36).
The stock traded between $3.41 and $4.01 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 194.17 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
GALT 52-Week Price Position
Position in Range: 29.2%
GALT is currently trading at $3.51, placing it 29.2% of the way from its 52-week low of $2.03 to its 52-week high of $7.13. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Galectin Therapeutics Inc. (GALT)?
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Galectin Therapeutics Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 9 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Galectin Therapeutics Inc. (GALT) Stock on MEXC
Eligible investors can buy real shares of Galectin Therapeutics Inc. (GALT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Galectin Therapeutics Inc. (GALT) stock price today?
2.Is GALT stock going up or down today?
3.What is GALT pre-market price?
4.What is GALT after-hours price?
5.Is GALT stock trading now?
6.Where does GALT sit relative to its 52-week high and low?
7.What sector is Galectin Therapeutics Inc. in?
8.What is Galectin Therapeutics Inc.'s market capitalization and where is it listed?
9.How is GALT valued in terms of P/E ratio and EPS?
10.Does Galectin Therapeutics Inc. pay a dividend?
Explore More US Stocks
Search Stocks
GALT Stock Calculator
Estimate the value between GALT shares and USD.
GALT Shares to USD
1.00 GALT shares = 3.514 USD
Calculations are estimates based on the latest available price and are for reference only.


